Quantcast

Reportlinker Adds Lung Cancer Therapeutics Report

September 8, 2009

NEW YORK, Sept. 8 /PRNewswire/ — Reportlinker.com announces that a new market research report is available in its catalogue.

Lung Cancer Therapeutics

http://www.reportlinker.com/p0131247/Lung-Cancer-Therapeutics.html

This report analyzes the worldwide markets (Annual Revenues) for Lung Cancer Therapeutics in Millions of US$. The US market for Non-Small Cell Lung Cancer treatment is further analyzed by: Chemotherapy Drugs, and Targeted Drugs. The report provides separate comprehensive analytics for the US, Europe and Rest of World. Annual forecasts are provided for each region for the period 2005 through 2015. The report profiles 191 companies including many key and niche players worldwide such as AstraZeneca PLC., Bristol-Myers Squibb Co., Eli Lilly & Co., F. Hoffmann-La Roche Ltd., Genentech, Inc., GlaxoSmithKline Plc., Novartis Pharmaceuticals Corporation, OSI Pharmaceuticals, Inc., Sanofi-Aventis, AbGenomics International Inc., ImClone Systems, Inc., Pfizer, Inc., Merck Serono International S.A., Merck & Co. Ltd., Telik, Inc., and Woomera Therapeutics, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1

Disclaimers I-2

Data Interpretation & Reporting Level I-2

Quantitative Techniques & Analytics I-3

Product Definitions and Scope of Study I-3

Chemotherapy Drugs I-3

Targeted Drugs I-3

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW II-1

Lung Cancer Therapeutics – Driven by Next Generation Drugs II-1

New Therapies Drive NSCLC Market II-1

Market Value of Taxanes to Decrease by 2015 II-2

Lung Cancer – The Killer Disease II-2

Lung Cancer – A Quick Glance at Global Statistics II-3

Asia Heading for Possible Lung Cancer Epidemic II-4

Table 1: Global Incidence of Lung Cancer (2008): Percentage

Share Breakdown by Region (includes corresponding Graph/

Chart) II-4

2. LUNG CANCER – AN INSIGHT II-5

Lungs – Critical for Oxygen Supply II-5

Lung Cancer – An Introduction II-5

Common Symptoms of Lung Cancer II-5

Types of Lung Cancer II-6

Non-Small Cell Lung Cancer II-6

NSCLC – At a Glance II-6

Small Cell Lung Cancer II-6

Risk Factors for Lung Cancer II-7

Female Smokers at Higher Risk of Developing Lung Cancer II-7

Lung Cancer Diagnostics II-7

Lung Cancer Staging II-8

Staging for Non-Small Cell Lung Cancer II-9

Staging for Small Cell Lung Cancer II-9

3. LUNG CANCER TREATMENT MODALITIES II-10

Surgery II-10

Radiation TherapyII-10

Chemotherapy II-10

Combination Therapy II-10

Photodynamic Therapy II-11

Vaccines II-11

Common Treatment Modalities for SCLC and NSCLC Lung Cancers II-11

Pain Management II-11

4. INTRODUCTION TO LUNG CANCER THERAPEUTICS II-12

Chemotherapy II-12

Drug Administration II-12

Overview of Chemotherapy Regimens and Drugs II-12

Side Effects of Chemotherapy II-13

Targeted Therapy II-13

Chemotherapy Drugs for SCLC Treatment II-13

Chemotherapy Drugs for NSCLC Treatment II-14

Major Chemotherapy Drugs II-14

Select Chemotherapy Drugs Used in the Treatment of Lung

Cancer by Brand and Generic Name II-14

Overview of Select Chemotherapeutic Drugs II-15

Alimta II-15

Carboplatin and Cisplatin II-15

Docetaxel II-16

Paclitaxel II-16

Xyotax II-17

Gemcitabine II-17

Gefitinib II-17

Irinotecan II-18

Vinorelbine (Navelbine(R)) II-18

5. PRODUCT DEVELOPMENT IN NSCLC THERAPEUTICS II-19

R&D Focus in NSCLC TreatmentII-19

Drug Development Process – Growth Opportunities & Challenges II-19

Product Pipeline for NSCLC Treatment II-20

Product Pipeline for NSCLC Treatment II-20

Select (Ongoing/Completed) Clinical Trials for NSCLC Treatment II-21

Companies Focus on Molecular Targeted Therapies II-22

Molecular Targeted Therapies – Overview of Select Product

Candidates II-22

Aflibercept (VEGF-Trap) – Sanofi Aventis/ Regeneron II-22

BIBW 2992 – Boehringer Ingelheim II-22

Erbitux (cetuximab) – ImClone/Merck Serono/Bristol- Myers

Squibb II-22

Nexavar (sorafenib) – Bayer Schering II-23

Recentin (cediranib) – AstraZeneca II-23

Sutent (sunitinib) – Pfizer II-23

Zactima (vandetanib) – AstraZeneca II-23

Zolinza (vorinostat) – Merck & Co II-23

Pipeline for Cytotoxic Therapy – Overview of Select Products II-24

Abraxane (albumin-bound paclitaxel) – Abraxis II-24

Glutoxim (NOV-002) – Novelos II-24

Javlor (vinflunine) – Pierre Fabre II-24

Lipoplatin (liposomal cisplatin) – Regulon II-24

Xyotax (paclitaxel polyglumex) – Cell Therapeutics/ Novartis II-24

6. PRODUCT APPROVALS/INNOVATIONS/ LAUNCHES II-25

Intas Biopharmaceuticals to Introduce Gefitinib in India II-25

Celgene Receives FDA Fast Track Product Designation for Amrubicin II-25

EMEA Approves ALIMTA for First-Line Therapy of Advanced NSCLC II-25

Celgene’s Cancer Drug Receives Orphan Drug Status from

European Commission II-25

Alimta Receives FDA Approval II-26

Roche Receives Approval from European Authorities for Avastin II-26

OSI Pharmaceuticals Introduces Tarceva in Japan II-26

Shanghai Medipharm Introduces TNT Antibody for Treating Lung

Cancer II-26

Natco Pharma Unveils an Injectible Drug for Lung Cancer, Pemnat II-26

Roche Scientific Introduces Tarceva in the Indian Market II-27

GlaxoSmithKline’s HYCAMTIN(R) Receives Marketing Approval from EC II-27

Genzyme Launches New Genetic Mutation Test to Aid Lung Cancer

Treatment II-27

UT Southwestern Medical Center Researchers Discover New Anti-

Cancer Drug II-28

Agennix’s Talactoferrin Alfa Program Obtains Fast Track

Designation from FDA II-28

Novelos Therapeutics’ NOV-002 Receives Fast Track Designation

from FDA II-28

7. RESEARCH & CLINICAL TRIALS II-29

Novartis Commences Phase III Clinical Trial of ASA404 II-29

Results of BR.21 Trials II-29

Genentech Announces Results of Phase III BETA Lung Trial II-29

Results of SATURN Clinical Trial II-29

Results of Zactima’s Clinical Trials II-30

Results of Erbitux’s Phase III Trials II-30

Results of Roche’s AVAiL Clinical Trial II-30

GlaxoSmithKline Conducts Phase III Clinical Trial of Lung

Cancer Vaccine II-31

FASgen Announces Research Results of FAS093 II-31

The Cuban Regulatory Agency Registers a New Therapeutic Lung

Cancer Vaccine II-31

Gemin X Commences Clinical Trials of GX15-070II-32

Antisoma and Biomira Announce Clinical Trial Results of Lung

Cancer Drugs II-32

OSI Pharmaceuticals Commences Phase III Clinical Trials of

Tarceva(R) II-33

Northwest Gets FDA Clearance to Conduct Clinical Trials for

Lung Cancer Vaccine II-33

University of Kentucky Conducts Clinical Trials on Lung Cancer

Vaccine II-33

Poniard Enrolls in Phase II Small Cell Lung Cancer Clinical

Trials of Picoplatin II-34

Sunesis Pharmaceuticals Starts Phase II Clinical Trials of

SNS-595 II-34

Ligand Pharmaceuticals Tables Clinical Results of Targretin(R) II-35

Bayer and Onyx Start Phase III Trial of Nexavar(R) II-35

Abraxis Announces Clinical Results of ABRAXANE(R) II-35

Introgen Conducts Phase II Clinical Trials of INGN 225 II-35

YM BioSciences Commences Clinical Trial of Nimotuzumab II-36

8. RECENT INDUSTRY ACTIVITY II-37

Merck Agrees to Merge with Shering-Plough II-37

Abbott Molecular Signs Agreement with Genentech, OSI and Roche II-37

IMUC Acquires Monoclonal Antibody Technology from MDC II-37

Quest PharmaTech Enters into Collaboration with BC Cancer Agency II-37

Daiichi Sankyo Acquires U3 Pharma II-38

MacroGenics Takes Over Raven Biotechnologies II-38

Roche Acquires Piramed II-38

Bristol-Myers Squibb Acquires Kosan Biosciences II-39

Point Therapeutics and DARA Biosciences Ink Merger Agreement II-39

Celgene Acquires Pharmion II-39

Pfizer to Takeover Serenex II-39

ATS Acquires Majority Stake in GANYMED Pharmaceuticals II-39

NCCN, AstraZeneca and Abraxis Enter into Collaboration II-40

Eli Lilly Agrees to Take Over ImClone SystemsII-40

CytRx Takes Over Innovive Pharmaceuticals II-40

Abbott Extends Discovery Partnership with Caprion II-41

Bristol-Myers and ImClone to Expand the Clinical Development

Program for ERBITUX II-41

Biomoda and New Mexico Tech Enter into a Collaborative Agreement II-42

Binex Inks Sponsored Research Agreement with MaxCyte II-42

Simcere Pharmaceutical Acquires Master Luck II-42

Dako Enters into Collaboration with OSI, Roche, and Genentech II-42

Biomira and Merck Sign Revised Supply and Collaboration

Agreements II-43

ImClone Systems Terminates Development Agreement with UCB II-43

Astellas Pharma’s US Subsidiary Acquires Agensys II-43

Antisoma Enters into an Agreement with Novartis II-44

Pharmacyclics Files NDA for Xcytrin(R) Injection II-44

9. FOCUS ON SELECT GLOBAL PLAYERS II-45

AstraZeneca PLC (UK) II-45

Bristol-Myers Squibb Co. (US) II-45

Eli Lilly & Co. (US) II-45

F. Hoffmann-La Roche Ltd (Switzerland) II-45

Genentech, Inc. (US) II-46

GlaxoSmithKline Plc (UK) II-46

Novartis Pharmaceuticals Corporation (US) II-46

OSI Pharmaceuticals, Inc. (US) II-46

Sanofi-Aventis (France) II-46

Companies with Pipeline Drugs II-47

AbGenomics International Inc. (US) II-47

ImClone Systems, Inc. (US)II-47

Pfizer, Inc. (US) II-47

Merck Serono International S.A. (Switzerland) II-47

Merck & Co. Ltd. (US) II-47

Telik, Inc. (US)II-48

Woomera Therapeutics, Inc. (US) II-48

10. GLOBAL MARKET PERSPECTIVE II-49

Table 2: World Recent Past, Current & Future Analysis for

Non-Small Cell Lung Cancer Therapeutics Market by Geographic

Region – US, Europe and Rest of World Independently Analyzed

with Annual Revenues in US$ Million for Years 2005 through

2015 (includes corresponding Graph/Chart) II-49

Table 3: World 10-Year Perspective for Non-Small Cell Lung

Cancer Therapeutics by Geographic Region – Percentage

Breakdown of Annual Revenues for US, Europe and Rest of World

Markets for Years 2006, 2009 & 2015 (includes corresponding

Graph/Chart) II-50

III. MARKET

1. THE UNITED STATES III-1

A.Market AnalysisIII-1

NSCLC Drug Market to Rise Sharply III-1

Lung Cancer Prevalence III-1

A Major Cause of Death among US Women III-1

Statistics III-2

Market Scenario III-3

FDA Places New Restrictions on Iressa III-3

Innovative Technology Enables Early Diagnosis of Lung Cancer III-3

Avastin to Emerge as the Preferred NSCLC Drug in the US III-3

Product Approvals/Clinical Trials/Introductions/ Launches III-4

Strategic Corporate Developments III-7

Key Players III-13

B.Market Analytics III-16

Table 4: US Recent Past, Current & Future Analysis for

Non-Small Cell Lung Cancer Therapeutics by Segment -

Chemotherapy Drugs and Targeted Drugs Markets Independently

Analyzed with Annual Revenues in US$ Million for Years 2005

through 2015 (includes corresponding Graph/Chart) III-16

Table 5: US 10-Year Perspective for Non-Small Cell Lung

Cancer Therapeutics by Segment – Percentage Breakdown of

Annual Revenues for Chemotherapy Drugs and Targeted Drugs

Markets for Years 2006, 2009 & 2015 III-16

2. EUROPE III-17

A.Market AnalysisIII-17

Lung Cancer Therapeutics Market to Witness Robust Growth III-17

Product Approvals III-17

Clinical TrialsIII-19

B.Market Analytics III-19

Table 6: European Recent Past, Current & Future Analysis for

Non-Small Cell Lung Cancer Therapeutics by Geographic Region

- France, Germany, Italy, UK and Rest of Europe

Independently Analyzed with Annual Revenues in US$ Million

for Years 2005 through 2015 (includes corresponding

Graph/Chart) III-19

Table 7: European 10-Year Perspective for Non-Small Cell

Lung Cancer Therapeutics Market by Geographic Region -

Percentage Breakdown of Annual Revenues for France, Germany,

Italy, UK and Rest of Europe Markets for Years 2006, 2009 &

2015 (includes corresponding Graph/Chart) III-20

2a. France III-21

A.Market AnalysisIII-21

Overview of Lung Cancer Market III-21

Key Player III-21

B.Market Analytics III-22

Table 8: French Recent Past, Current & Future Analysis for

Non-Small Cell Lung Cancer Therapeutics Market Analyzed with

Annual Revenues in US$ Million for Years 2005 through 2015

(includes corresponding Graph/Chart) III-22

2b. GERMANY III-23

A.Market AnalysisIII-23

Lung Cancer Scenario III-23

Chemotherapy Gains Preference III-23

Strategic Corporate Developments III-24

B.Market Analytics III-25

Table 9: German Recent Past, Current & Future Analysis for

Non-Small Cell Lung Cancer Therapeutics Market Analyzed with

Annual Revenues in US$ Million for Years 2005 through 2015

(includes corresponding Graph/Chart) III-25

2c. ITALY III-26

A.Market AnalysisIII-26

Incidence in Women on Rise III-26

Treatment III-26

B.Market Analytics III-26

Table 10: Italian Recent Past, Current & Future Analysis for

Non-Small Cell Lung Cancer Therapeutics Market Analyzed with

Annual Revenues in US$ Million for Years 2005 through 2015

(includes corresponding Graph/Chart) III-26

2d. THE UNITED KINGDOM III-27

A.Market AnalysisIII-27

British Women at Higher Risk III-27

Fast Facts III-27

Proposed Cancer Care Improvements Mulled by British Government III-27

NICE Recommends Use of Erlotinib in NSCLC Treatment III-28

Strategic Corporate Developments III-28

Key Players III-29

B.Market Analytics III-29

Table 11: UK Recent Past, Current & Future Analysis for

Non-Small Cell Lung Cancer Therapeutics Market Analyzed with

Annual Revenues in US$ Million for Years 2005 through 2015

(includes corresponding Graph/Chart) III-29

2e. REST OF EUROPE III-30

A.Market AnalysisIII-30

Outlook III-30

Strategic Corporate Developments III-30

Key Player III-30

B.Market Analytics III-31

Table 12: Rest of Europe Recent Past, Current & Future

Analysis for Non-Small Cell Lung Cancer Therapeutics Market

Analyzed with Annual Revenues in US$ Million for Years 2005

through 2015 (includes corresponding Graph/Chart) III-31

3. REST OF WORLD III-32

A.Market AnalysisIII-32

Australia III-32

Fast Facts III-32

Brazil III-32

China III-32

Overview of NSCLC Drug Market III-32

India III-33

Japan III-33

Product Launches III-33

Strategic Corporate Development III-35

B.Market Analytics III-36

Table 13: Rest of World Recent Past, Current & Future

Analysis for Non-Small Cell Lung Cancer Therapeutics Market

Analyzed with Annual Revenues in US$ Million for Years 2005

through 2015 (includes corresponding Graph/Chart) III-36

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 191 (including Divisions/Subsidiaries – 200)

To order this report:

Lung Cancer Therapeutics

http://www.reportlinker.com/p0131247/Lung-Cancer-Therapeutics.html

More market research reports here!

    Nicolas Bombourg
    Reportlinker
    Email: nbo@reportlinker.com
    US: (805)652-2626
    Intl: +1 805-652-2626

SOURCE Reportlinker


Source: newswire



comments powered by Disqus